أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

arysta lifescience australia pty ltd - dicamba present as the dimethylamine salt - aqueous concentrate - dicamba present as the dimethylamine salt benzoic acid-arylaliphatic active 500.0 g/l - herbicide - barley | commercial rye | conservation tillage weed control | grass pasture | grasses | non-crop area - general | oats | pasture - afghan thistle | amaranth or amaranthus | angled onion | annual gooseberry | annual or common ragweed | annual phalaris | annual ryegrass | apple-of-peru | artichoke thistle | barnyard or water grass | bathurst burr | bellvine | bindweed | bindy-eye | bitter bark or quinine tree | black bindweed | black or brisbane black wattle | blackberry nightshade | blue gum | blue heliotrope or blue top | broadleaf dock | burr ragweed | californian thistle | calopo | caltrop or yellow vine | canary grass | capeweed | cat's ears or flatweeds | centro | charlock | chickweed | cleome | climbing buckwheat | clover | clover - seedling | cobbler's pegs | common iceplant | common vetch or tares | convolvulus vines | cotton thistle | cotulas | creeping knotweed | creeping oxalis | creeping/russian knapweed,hardhead | cudweed | curled dock | dandelion - hypochaeris glabra | datura spp. | deadnettle | dock | dock - seedling | fat hen | fleabane | fumitory | galvanised burr | giant or black pigweed | gooseberry | green amaranth | g

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - dicamba present as the dimethylamine salt - aqueous concentrate - dicamba present as the dimethylamine salt benzoic acid-arylaliphatic active 500.0 g/l - herbicide - barley - see label | between cropping | commercial rye - see label | conservation tillage weed control | direct drill | fallow ( - afghan thistle | amaranth - seedling | amaranth or amaranthus | angled onion | annual gooseberry | annual gooseberry - seedling | annual or common ragweed | annual or wimmera ryegrass | annual phalaris | apple-of-peru | artichoke thistle | barnyard or water grass | bathurst burr | bathurst burr - seedling | bellvine | bellvine - seedling | bindy-eye | bitter bark or quinine tree | black bindweed | black or brisbane black wattle | blackberry nightshade | blackberry nightshade - seedling | bladder campion | bladder ketmia | blue gum | blue heliotrope or blue top | burr ragweed | californian thistle | calopo | caltrop or yellow vine | caltrop or yellow vine - seedling | capeweed | cat's ear or flatweed | centro - seedling | charlock | chickweed | cleome | cleome - seedling | clover | cobbler's pegs | cobbler's pegs - seedling | common iceplant | convolvulus - seedling | convolvulus genus | cotulas | creeping knotweed | creeping oxalis | creeping/russian knapweed,hardhead | cudweed | dandelion - taraxacum officin

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; hydrogenated vegetable oil; magnesium stearate; croscarmellose sodium; pregelatinised maize starch - supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg wolff-parkinson-white and lown-ganong-levine syndromes. (b) due to dual av nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although tambocor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, tambocor should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of tambocor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous tambocor is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requir

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hydrogenated vegetable oil; magnesium stearate; pregelatinised maize starch - supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg wolff-parkinson-white and lown-ganong-levine syndromes. (b) due to dual av nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although tambocor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, tambocor should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of tambocor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous tambocor is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requir

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 10 mg/ml - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate; water for injections - supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg wolff-parkinson-white and lown-ganong-levine syndromes. (b) due to dual av nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although tambocor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, tambocor should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of tambocor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous tambocor is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requir

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - dicamba as the sodium salt - water dispersible granule - dicamba as the sodium salt benzoic acid-arylaliphatic active 700.0 g/kg - herbicide

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

isk biosciences oceania pty ltd - fluazinam - suspension concentrate - fluazinam anilide/aniline-dinitro active 500.0 g/l - fungicide - apple | broccoli | brussels sprouts | cabbage | cauliflower | grapevine | kohlrabi | delicious | golden delicious | granny smith - club root | leaf blight - phomopsis viticola | phomopsis cane | white root rot | phomopsis cane | soil fungi

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

aubex pharma pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: hydrogenated vegetable oil; purified water; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; magnesium stearate - bpa-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although bpa-flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, bpa-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of bpa-flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,bpa-flecainide tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.,prescribers should also consult the "special warnings and precautions for use" section of this product information.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

aubex pharma pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; hydrogenated vegetable oil; purified water; croscarmellose sodium - bpa-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although bpa-flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, bpa-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of bpa-flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,bpa-flecainide tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.,prescribers should also consult the "special warnings and precautions for use" section of this product information.

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - azoxystrobin; tebuconazole - suspension concentrate - azoxystrobin pyrimidine active 120.0 g/l; tebuconazole triazole active 200.0 g/l - fungicide